---
title: "H.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286220698.md"
description: "H.C. Wainwright analyst Swayampakula Ramakanth has maintained a Buy rating on Eton Pharmaceuticals (ETON) with a price target of $52.00, while the stock closed at $29.71. Ramakanth, a 5-star analyst, has an average return of 18.9% and a 43.31% success rate. Eton has a Strong Buy consensus with a price target of $41.00, indicating a 38% upside. Craig-Hallum also reiterated a Buy rating with a $40.00 target."
datetime: "2026-05-13T08:07:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286220698.md)
  - [en](https://longbridge.com/en/news/286220698.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286220698.md)
---

# H.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)

In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals, with a price target of $52.00. The company’s shares closed yesterday at $29.71.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Ramakanth is a 5-star analyst with an average return of 18.9% and a 43.31% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Corcept Therapeutics, and Evotec AG.

Eton Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $41.00, a 38.00% upside from current levels. In a report released on May 4, Craig-Hallum also reiterated a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [MIRM.US](https://longbridge.com/en/quote/MIRM.US.md)
- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)
- [EVT.DE](https://longbridge.com/en/quote/EVT.DE.md)
- [EVO.US](https://longbridge.com/en/quote/EVO.US.md)

## Related News & Research

- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)